[Ip-health] Alan Sager: It's Time to Confront the Drug Makers

Jamie Love james.love at keionline.org
Tue Aug 9 09:28:20 PDT 2016

$100 billion for an Alzheimer treatment would be wasteful, because the
developer of the product would have come in at the end of a long publicly
funded research project, and risked not that much once the science had
progressed.   The mistake is to think the prize incentives is to match the
benefit to society rather than the incentive needed to bring the product to


On Tue, Aug 9, 2016 at 11:24 AM, Peter Maybarduk <pmaybarduk at citizen.org>

> In "Democracy: A Journal of Ideas"
> August 8
> http://democracyjournal.org/arguments/its-time-to-
> confront-the-drug-makers/
> "One mechanism for doing this would be for government to finance
> innovation by abolishing, or limiting, patents and, instead, awarding
> prizes in fair proportion to new drugs' value. (A $100 billion prize for a
> safe and effective drug for Alzheimer's would be conservative. The prize
> would be modulated over time as evidence grows on a new med's efficacy,
> safety, and the averted costs of other treatments.) In return for the
> prize, a public body would license the innovation for production and sale
> at low prices-adequate to cover costs of manufacturing and distribution.
> The prize mechanism has been advocated by Sen. Sanders, who has
> reintroduced the Medical Innovation Prize Fund Act on several occasions, as
> well as economist Joseph Stiglitz."
> _______________________________________________
> Ip-health mailing list
> Ip-health at lists.keionline.org
> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org

James Love.  Knowledge Ecology International
KEI DC tel: +1.202.332.2670, US Mobile: +1.202.361.3040, Geneva Mobile:
+41.76.413.6584, twitter.com/jamie_love

More information about the Ip-health mailing list